-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PqD8uaNKppdnNagv3OP/uCrb3KvcqN8BRFVl57ID7o22GlFZDbXwyLGsiekrm9rs gu2yidX5IVwk7l/uA0TKcA== 0001367982-06-000186.txt : 20061207 0001367982-06-000186.hdr.sgml : 20061207 20061207153050 ACCESSION NUMBER: 0001367982-06-000186 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061205 FILED AS OF DATE: 20061207 DATE AS OF CHANGE: 20061207 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GRAHAM GINGER L CENTRAL INDEX KEY: 0001192601 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 061262532 BUSINESS ADDRESS: BUSINESS PHONE: 8586427002 MAIL ADDRESS: STREET 1: AMYLIN PHARMACEUTICALS, INC. STREET 2: 885 ARAPAHOE AVENUE CITY: BOULDER STATE: CO ZIP: 80302 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2006-12-05 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001192601 GRAHAM GINGER L 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 0 1 0 0 Chief Executive Officer Common Stock 2006-12-05 4 M 0 2173 23 A 144082 D Incentive Stock Option (right to buy) 23 2006-12-05 4 M 0 2173 0 D 2013-06-06 Common Stock 2173 4347 D Include 413 shares acquired on July 31,2006 through the Company's Employee Stock Purchase Plan. One-fourth (1/4) of this option grant vested on June 6, 2004 with the remainder of the grant vesting monthly over the next three years becoming fully-vested four years from the date of grant. By: /s/Darin M. Lippoldt, Attorney-in-Fact For: Ginger L. Graham 2006-12-07 -----END PRIVACY-ENHANCED MESSAGE-----